Jingmin ZhouPhD

Co-Founder and CEO


• More than 15 years as an AAV CMC professional, long-term experience with GMP manufacturing of multiple AAV serotypes. Contributions to 12 successful INDs and 1 BLA approval from FDA & EMA

• Previously Senior Director responsible for CMC at Prevail Therapeutics (acquired by Eli Lilly in Dec. 2020)

• CMC leadership in Intrexon Corporation, Spark Therapeutics, and SIO Gene Therapies

• BS from Peking University, and PhD from Tsukuba University, Japan



Xinde Hu, PhD

Co-Founder and VP of Gene Therapy Design



• Deep experience in gene therapy design and ophthalmology biology

• 2016-2022.9, Assistant Researcher, PhD candidate, postdoc at CAS

• 2009-2016, B.S. and MS from Northwest A&F University

Jinlin Su, PhD

Co-Founder and VP of CNS Biology



• Deep experience in gene therapy design and ophthalmology biology

• 2012-2022.9, PhD candidate, Assistant Researcher at CAS

• 2008-2012, B.S. from Jilin University

Haibo Zhou, PhD

Founder and Chief Scientific Advisor


• Currently a PI at Center for Excellence in Brain Science and Intelligence Technology (CEBSIT) /Institute of Neuroscience, Chinese Academy of Sciences (CAS)

• Previous works published in Cell, Nature, Nature Neuroscience, Nature Cell Biology, National Science Review, and eLife

• Master & PhD, Neuroscience, Erasmus Medical Center, the Netherlands

Qi Jin

Co-Founder and Chief Business Advisor


• Currently Managing Partner at Kaitai Capital

• 10 years of early-stage biotech investment experience with extensive experience in company formation

• BS from Zhejiang University, MS from Imperial College, UK